Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Johansson, Per ^a,b   Almqvist, Erik G ^c   Wallin, Anders ^b   Johansson, Jan Ove ^b   Andreasson, Ulf ^b   Blennow, Kaj ^b   Zetterberg, Henrik ^b,d   Svensson, Johan ^b,c  

^a Department of Neuropsychiatry Skaraborg Central Hospital   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-42]; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TAU PROTEIN; VASCULOTROPIN A; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; FEMALE; GENDER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; WAIST HIP RATIO; AGED; ALZHEIMER DISEASE; BLOOD; CAUCASIAN; CEREBROSPINAL FLUID; COHORT ANALYSIS; IMMUNOLOGY; MENTAL HEALTH; PHOSPHORYLATION; SWEDEN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BODY MASS INDEX; COGNITIVE DYSFUNCTION; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; MALE; MENTAL STATUS SCHEDULE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SWEDEN; TAU PROTEINS;

EID: 85018951326     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0176760     Document Type: Article

References (52)

1. Dinarello C. Historical insights into cytokines. Eur J Immunol. 2007; 37 Suppl 1:S34-S45.
2. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016; 12:719-32. https://doi.org/10.1016/j.jalz.2016.02.010 PMID: 27179961
3. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010; 24:548-59. https://doi.org/10.1096/fj.09-141754 PMID: 19825975
4. Ghosh S, Wu M, Shaftel S, Kyrkanides S, LaFerla F, Olschowka J, et al. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci. 2013; 33:5053-64. https://doi.org/10.1523/JNEUROSCI.4361-12.2013 PMID: 23486975
5. Vom Berg J, Prokop S, Miller K, Obst J, Kä lin R, Lopategui-Cabezas I, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med. 2012; 18:1812-9. https://doi.org/10.1038/nm.2965 PMID: 23178247
6. Tan M, Yu J, Jiang T, Zhu X, Guan H, Tan L. IL12/23 p40 inhibition ameliorates Alzheimer's diseaseassociated neuropathology and spatial memory in SAMP8 mice. J Alzheimers Dis. 2014; 38:633-46. https://doi.org/10.3233/JAD-131148 PMID: 24047617
7. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere A, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease J Neurosci. 2003; 23:7504-9. PMID: 12930788
8. Yip A, Green R, Huyck M, Cupples L, Farrer L, Study Group M. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr. 2005; 5:2. https://doi.org/10.1186/ 1471-2318-5-2 PMID: 15647106
9. Vlad S, Miller D, Kowall N, Felson D. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008; 70:1672-7. https://doi.org/10.1212/01.wnl.0000311269.57716.63 PMID: 18458226
10. Gupta P, Pandey R, Jha D, Shrivastav V, Kumar S. Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials. Am J Alzheimers Dis Other Demen. 2015; 30:178-82. https://doi.org/10.1177/1533317514542644 PMID: 25024454
11. Wang J, Tan L, Wang H, Tan C, Meng X, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2015; 44:385-96. https:// doi.org/10.3233/JAD-141506 PMID: 25227314
12. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010; 68:930-41. https://doi.org/10.1016/j.biopsych.2010.06. 012 PMID: 20692646
13. Pasqualetti G, Brooks J, Edison P. The role of neuroinflammation in dementias. Curr Neurol Neurosci Rep. 2015; 15:17. https://doi.org/10.1007/s11910-015-0531-7 PMID: 25716012
14. Chen A, Oakley A, Monteiro M, Tuomela K, Allan L, Mukaetova-Ladinska E, et al. Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Neurobiol Aging. 2016; 38:56-67. https://doi.org/10.1016/j.neurobiolaging.2015.10.021 PMID: 26827643
15. Koyama A, O'Brien J, Weuve J, Blacker D, Metti A, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013; 68:433-40. https://doi.org/10.1093/gerona/gls187 PMID: 22982688
16. Kovacs G, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord. 2008; 26:343-50. https://doi.org/10.1159/000161560 PMID: 18849605
17. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson J, Andreasson U, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis. 2011; 24:537-46. https://doi.org/10.3233/JAD-2011-101878 PMID: 21297262
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939-44. PMID: 6610841
19. Román G, Tatemichi T, Erkinjuntti T, Cummings J, Masdeu J, Garcia J, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993; 43:250-60. PMID: 8094895
20. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. Neural Transm Suppl. 2000; 59:23-30.
21. Petersen R. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-94. https:// doi.org/10.1111/j.1365-2796.2004.01388.x PMID: 15324362
22. Folstein M, Folstein S, McHugh P. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-98. PMID: 1202204
23. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse M, Andreasen N, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000; 7:245-58. PMID: 11132093
24. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995; 26:231-45. https://doi.org/10.1007/BF02815140 PMID: 8748926
25. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000; 285:49-52. PMID: 10788705
26. Kalb A, von Haefen C, Sifringer M, Tegethoff A, Paeschke N, Kostova M, et al. Acetylcholinesterase inhibitors reduce neuroinflammation and -degeneration in the cortex and hippocampus of a surgery stress rat model. PloS One. 2013; 8:e62679. https://doi.org/10.1371/journal.pone.0062679 PMID: 23671623
27. Rasmuson S, Näsman B, Olsson T. Increased serum levels of dehydroepiandrosterone (DHEA) and interleukin-6 (IL-6) in women with mild to moderate Alzheimer's disease. Int Psychogeriatr. 2011; 23:1386-92. https://doi.org/10.1017/S1041610211000810 PMID: 21729423
28. Helmy A, Naseer M, Shafie S, Nada M. Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegener Dis. 2012; 9:81-6. https://doi.org/10.1159/000329568 PMID: 22133543
29. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, et al. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J Neurol. 2008; 255:539-44. https://doi.org/10.1007/s00415-008-0737-6 PMID: 18204920
30. Jia J, Meng R, Sun Y, Sun W, Ji X, Jia L. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett. 2005; 383:12-6. https://doi. org/10.1016/j.neulet.2005.03.051 PMID: 15936505
31. Kim S, Song J, Kim S, Han C, Park M, Koh Y, et al. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol. 2011; 11:51. https://doi.org/10.1186/ 1471-2377-11-51 PMID: 21569380
32. Huang L, Jia J, Liu R. Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment. Neurosci Lett. 2013; 550:60-3. https://doi.org/ 10.1016/j.neulet.2013.06.031 PMID: 23827227
33. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006; 21:9-15. https://doi.org/10.1159/000089137 PMID: 16244482
34. Motta M, Imbesi R, Di Rosa M, Stivala F, Malaguarnera L. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett. 2007; 114:46-51. https://doi.org/10.1016/j.imlet.2007.09.002 PMID: 17949824
35. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol. 2008; 193:183-7. https://doi.org/10.1016/j.jneuroim. 2007.10.020 PMID: 18037502
36. Tarkowski E, Issa R, Sjögren M, Wallin A, Blennow K, Tarkowski A, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002; 23:237-43. PMID: 11804709
37. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006; 63:538-43. https://doi.org/10.1001/archneur.63.4.538 PMID: 16606766
38. Rentzos M, Zoga M, Paraskevas G, Kapaki E, Rombos A, Nikolaou C, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Geriatr Psychiatry Neurol. 2006; 19:114-7. https://doi.org/10.1177/0891988706286226 PMID: 16690997
39. Alsadany M, Shehata H, Mohamad M, Mahfouz R. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013; 28:54-61. https:// doi.org/10.1177/1533317512467680 PMID: 23242124
40. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PloS One. 2012; 7:e30525. https://doi.org/10.1371/journal.pone.0030525 PMID: 22303443
41. Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D, et al. IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. Eur J Neurol. 2007; 14:e3-e4.
42. Zhang R, Miller R, Madison C, Jin X, Honrada R, Harris W, et al. Systemic immune system alterations in early stages of Alzheimer's disease. J Neuroimmunol. 2013; 256:38-42. https://doi.org/10.1016/j. jneuroim.2013.01.002 PMID: 23380586
43. Xia M, Bacskai B, Knowles R, Qin S, Hyman B. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol. 2000; 108:227-35. PMID: 10900358
44. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46. https://doi.org/10.1038/nri1001 PMID: 12563297
45. Croxford A, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev 2014; 25:415-21. https://doi.org/10.1016/j.cytogfr.2014.07.017 PMID: 25130295
46. Zhu X, Tan L, Jiang T, Tan M, Zhang W, Yu J. Association of IL-12A and IL-12B polymorphisms with Alzheimer's disease susceptibility in a Han Chinese population. J Neuroimmunol. 2014; 274:180-4. https://doi.org/10.1016/j.jneuroim.2014.06.026 PMID: 25037175
47. Liu Y, Yu J, Zhang W, Zong Y, Lu R, Zhou J, et al. Interleukin-23 receptor polymorphisms are associated with Alzheimer's disease in Han Chinese. J Neuroimmunol. 2014; 271:43-8. https://doi.org/10.1016/j.jneuroim.2014.03.013 PMID: 24703098
48. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006; 27:33-9. https://doi.org/10.1007/s10072-006-0562-6 PMID: 16688597
49. Engelborghs S, De Brabander M, De Crée J, D'Hooge R, Geerts H, Verhaegen H, et al. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int. 1999; 34:523-30. PMID: 10402228
50. Rentzos M, Paraskevas G, Kapaki E, Nikolaou C, Zoga M, Rombos A, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Neurol Sci. 2006; 249:110-4. https://doi.org/10.1016/j.jns.2006.05.063 PMID: 16843497
51. Horvath I, Jia X, Johansson P, Wang C, Moskalenko R, Steinau A, et al. Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer's disease. ACS Chem Neurosci. 2016; 7:34-9. https://doi.org/10.1021/acschemneuro.5b00265 PMID: 26550994
52. Trollor J, Smith E, Baune B, Kochan N, Campbell L, Samaras K, et al. Systemic inflammation is associated with MCI and its subtypes: the Sydney Memory and Aging Study. Dement Geriatr Cogn Disord. 2010; 30:569-78. https://doi.org/10.1159/000322092 PMID: 21252552